Enterprise Value

40.56B

Cash

8.923B

Avg Qtr Burn

N/A

Short % of Float

6.36%

Insider Ownership

9.61%

Institutional Own.

68.33%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

mRNA-1345 Details
Respiratory syncytial virus

BLA

Submission

Phase 3

Data readout

Phase 3

Data readout

mRNA-1647 Details
Cytomegalovirus

Phase 3

Interim Update

Phase 3

Initiation

mRNA-1468 Details
Varicella-zoster virus

Phase 1/2

Interim update

mRNA-3927 Details
Propionic acidemia

Phase 1/2

Update

mRNA-1574 Details
(HIV) human immunodeficiency virus

Phase 1

Data readout